Pharmaceutical Research and Development

Investment on pharmaceutical research and development Despite the fact that they are projected to increase at a compound annual growth rate (CAGR) of 2.8% through 2022, stakeholders and experts have noticed a decline in the return on investment (ROI). Pharmaceutical firms are coming under more and more pressure to either increase the success rates of their R&D or lower the cost of failure, which a breakthrough would ordinarily pay. From the first hazardous dose through market approval, the pharma research and development process has an average success rate of 4.9%. However, experts are debating whether the number of FDA-approved pharmaceuticals in 2016 was lower than in 2015, which raises the possibility that drug approvals have already peaked and will continue to drop. with a dismal forecast for increasing pharmaceutical research and development success rates.

    Related Conference of Pharmaceutical Research and Development

    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Pharmaceutical Research and Development Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in